Remimazolam Tosilate
Phase 3Small molecule
Remimazolam Tosilate is one of 74 small molecule programs targeting Muscle Relaxants. It is currently in Phase 3.
4
Indications
16
Total Trials
1
Active Trials
73
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
88 competitors in Cognition
#DrugCompanyPhaseTrials
1Vyvanse
TakedaApproved
Zocor
OOrganon and Co
Approved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Accutane
CConrado Roberto Hoffmann Filho
Approved
Namenda
AbbViePhase 3
Fintepla
UCBApproved
Epidiolex
Jazz PharmaceuticalsPhase 2
Nuplazid
AACADIA Pharmaceuticals Inc.
Phase 2
Remimazolam Tosilate
FFujian Shengdi Pharmaceutical Co., Ltd.
Phase 3
Psilocybin
COMPASS PathwaysPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sedation5 trials
Remimazolam4 trials
Muscle Relaxants1 trial
Cognition1 trial
4 more indications
General Anaesthesia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Remimazolam Tosilate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details